Profound Medical to Present First CAPTAIN Trial Results Comparing TULSA Procedure to Robotic Prostatectomy
核心洞察
Profound Medical will present first clinical outcomes from the CAPTAIN trial comparing the MRI-guided TULSA Procedure (搜索) to robotic radical prostatectomy in localized prostate cancer at the European Association of Urology Congress on March 13, 2026.
The Level 1 post-market trial represents a pivotal evidence milestone for ablative prostate therapies, designed to generate guideline-grade evidence on oncologic control and functional outcomes versus the established surgical standard.
The comparative data could potentially influence European clinical guidance and payer assessments, with implications for treatment guideline inclusion and broader adoption of the incision-free therapy.
Profound Medical Corp (搜索). is set to unveil the first clinical outcomes from its pivotal CAPTAIN trial, a head-to-head comparison of the company's MRI-guided TULSA Procedure (搜索) against robotic radical prostatectomy in men with localized prostate cancer. The results will be presented during the Late-Breaking and High-Impact session at the 41st Annual European Association of Urology Congress in London on March 13, 2026.
The presentation, delivered by Dr. Laurence Klotz, a professor of surgery at the University of Toronto and Sunnybrook Chair of Prostate Cancer Research, marks a critical inflection point for ablative prostate therapies. Following the EAU presentation, Profound Medical will host an investor webinar at 11:30 a.m. EDT, where Dr. Klotz will review the clinical data and management will discuss commercial implications and next steps toward potential treatment guideline inclusion.
CAPTAIN Trial Significance
The CAPTAIN study represents the first Level 1 post-market trial designed to generate guideline-grade evidence comparing TULSA's safety and efficacy against robotic prostatectomy, the current surgical standard. While TULSA is already cleared in multiple markets including the United States, Europe, Canada, and several other regions, broad adoption has been constrained by the absence of randomized, head-to-head data against established surgical standards.
The trial is strategically designed to close this evidence gap by providing comparative data on oncologic control and functional outcomes. The timing and venue of the presentation signals an explicit effort to influence European clinical guidance and payer assessments first, with expectations that favorable results could extend to U.S. stakeholders and other regions.
Technology and Treatment Approach
The TULSA Procedure (搜索) utilizes MRI-guided, incision-free prostate therapy designed for precision and flexibility. The technology allows physicians to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment approaches.
This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and benign prostatic hyperplasia, while potentially minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and erectile dysfunction.
Clinical and Commercial Implications
The comparative framework against robotic prostatectomy is strategically significant, as robotics currently dominates surgical market share and reimbursement while setting the benchmark for perioperative safety and cancer control. If CAPTAIN demonstrates non-inferiority on oncologic endpoints with measurable advantages in continence and potency preservation, it could fundamentally recalibrate how guideline panels weigh trade-offs between cure and quality of life in localized disease.
For healthcare providers, supportive data would have significant operational implications. TULSA shifts treatment volume from the operating room to the MRI suite, requiring protected scanner time, anesthesia support, and integrated workflows between urology and radiology departments. Implementation would necessitate new credentialing pathways, proctoring programs, and care maps for post-ablation surveillance, including specialized imaging and biopsy protocols.
Market and Regulatory Outlook
The forward path following the data presentation involves leveraging results for guideline submissions, targeted economic models, and expansion of post-market registries. Key factors for successful adoption include consistent performance across diverse clinical sites, which would strengthen the case for rapid inclusion in EAU and later NCCN frameworks, as well as support health technology assessments and payer engagement processes.
Critical evaluation points will include the trial's primary hypothesis design, risk-stratified enrollment, follow-up duration for assessing biochemical recurrence, retreatment and crossover rates, complications requiring hospitalization, and learning-curve effects across participating centers. The scalability of benefits across different operator skill levels and MRI infrastructure capabilities will be particularly important for broader implementation.
The unresolved questions surrounding durability, generalizability, and operational throughput will ultimately determine whether TULSA can scale from promising technology to standard treatment option in localized prostate cancer management.